ALTEOGEN Inc

Novartis has signed a drug-delivery agreement worth up to $3.22 billion with Alteogen, aiming to convert intravenous biologic medicines into faster under-the-skin injections. The deal, which covers several potential products using Alteogen's Hybrozyme platform and ALT-B4 enzyme, is not an upfront payment; most of the money depends on achieving development, regulatory, and commercial milestones. Novartis shares slipped 0.1% to $161.05 on Wednesday, and the stock trades 23.11% above its GF Value estimate of $130.82, indicating investors are paying a premium for future execution.

Alteogen Inc. has entered into an option and license agreement with Novartis for the development and commercialization of subcutaneous products using its ALT-B4 enzyme, powered by the Hybrozyme platform. Under the deal, Novartis obtains multiple options to secure exclusive rights to develop and commercialize subcutaneous formulations for several of its products, leveraging ALT-B4 to convert intravenous biologics into more convenient subcutaneous injections. If all options are exercised and milestones met, Alteogen could receive up to US$3,223 million, including option fees, milestone payments, and royalties. This marks Alteogen's fourth licensing agreement this year, underscoring the growing value of its Hybrozyme technology. Alteogen's CEO, Tae-Yon Chun, highlighted the agreement as evidence of the platform's technological strength and commercial potential.